Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry | Targeted Oncology
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC - Medical Conferences
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey - George - 2023 - Cancer Medicine - Wiley Online Library
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
Targeted Alpha Therapy Optimising Survival in Advanced Prostate Cancer
PROpel Trial Efficacy – LYNPARZA® (olaparib) for BRCAm mCRPC
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine
Medicus Economics, LLC on LinkedIn: Real-world treatment patterns and overall survival among men with…
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Pluvicto Delays Progression in Earlier mCRPC, but Crossover Muddies Overall Survival Analysis | Precision Medicine Online
Latest developments in prostate cancer treatment
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
Efficacy I PLUVICTO
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer - Chung-Shien Lee, So Yi Lam, Angel Liu, Cristina Sison, Xin-Hua Zhu, 2023
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
